#FluTreatment

Exciting news from #TaiGen Biotechnology! Their Influenza Antiviral TG-1000 has shown positive results in Phase III trial, alleviationing symptoms 27 hours earlier than the placebo, with a statistically significant difference.

It is expected that TaiGen’s Chinese partner, Joincare Pharmaceutical Group Industry Co., Ltd., will file a new drug application for TG-1000 in China in the second half of the year.

Chairman and CEO, Philip Kuo-Lung Huang, highlighted the surge in flu cases from 2023 to 2024, indicating a growing trend of coexistence between flu viruses and humans. With the successful results of study for the TG-1000, the market potential for innovative flu drugs looks promising! 

Read more: https://lnkd.in/gCGQj_fZ 

Stay updated on more groundbreaking discoveries in biotechnology with #Globalbio! 

#TaiGen